Printer Friendly

GENSIA LABORATORIES RECEIVES ANDA APPROVAL FOR SODIUM NITROPRUSSIDE

GENSIA LABORATORIES RECEIVES ANDA APPROVAL FOR SODIUM NITROPRUSSIDE
 SAN DIEGO, March 31 /PRNewswire/ -- Gensia Pharmaceuticals Inc. (NASDAQ: GNSA) today announced that Gensia Laboratories Ltd. (a wholly owned subsidiary of Gensia Pharmaceuticals) has received an Abbreviated New Drug Application (ANDA) approval from the Food and Drug Administration (FDA) to market intravenous sodium nitroprusside. With this approval, Gensia Laboratories now has 16 approved ANDAs covering 12 multi-source (generic) drugs, according to David F. Hale, chairman, president and chief executive officer of Gensia Pharmaceuticals.
 Sodium nitroprusside is an intravenous cardiovascular drug indicated for use in the immediate reduction of blood pressure of patients in hypertensive crisis or for producing controlled hypotension during anesthesia to reduce bleeding. Gensia Laboratories will sell sodium nitroprussside in a liquid-fill vial.
 Since its acquisition, Gensia Laboratories has received 11 ANDA approvals to market nine intravenous drugs including aminophylline, dopamine, gentamicin, glycopyrrolate, methyldopate, metoclopramide, sodium nitroprusside, SMX/TMP and tobramycin. An additional five ANDAs on three drugs were acquired with the purchase of Gensia Laboratories.
 "The Gensia Laboratories sales force is marketing a growing line of injectable multi-source drugs," said Hale. "We expect additional approvals on pending ANDAs throughout this year."
 Gensia Laboratories is located in Irvine, Calif. and manufactures multi-source injectable drug products for the acute-care, hospital market.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases.
 -0- 3/31/92
 /CONTACT: David F. Hale or Martha L. Hough of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA) CO: Gensia Pharmaceuticals ST: California IN: MTC SU:


AL-KJ -- SD004 -- 3379 03/31/92 11:38 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1992
Words:270
Previous Article:SEARS COMPLETES STUDY, RELEASES ANNUAL REPORT
Next Article:CARPENTER ELECTS TWO NEW DIRECTORS
Topics:


Related Articles
ROYCE LABORATORIES RECEIVES FDA APPROVAL FOR LORAZEPAM IN THREE DOSAGE STRENGTHS
GENSIA LABORATORIES RECEIVES ANDA APPROVALS FOR INJECTABLE ANTI-INFECTIVE AND ADJUNCT TO CHEMOTHERAPY
GENSIA LABORATORIES RECEIVES AADA APPROVAL FOR INJECTABLE DOXORUBICIN FIRST GENSIA APPROVAL FOR ONCOLYTIC PRODUCT IN A PLASTIC VIAL
GENSIA LABORATORIES RECEIVES ANDA APPROVAL FOR ETOPOSIDE IN 50mL VIAL
GENSIA LABORATORIES RECEIVES ANDA APPROVAL FOR FLUPHENAZINE INJECTION
Gensia Laboratories and Microbix Complete Licensing Agreement for Acute Cardiovascular Product
Gensia Laboratories Receives First U.S. Generic Approval for Leucovorin Calcium in 350 mg Vial
Gensia Laboratories Receives ANDA Approval For Desmopressin Acetate Injection

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters